17,261 trials
Urologic Diseases · Urinary Bladder Diseases · Urological Manifestations
Primary: Change From Baseline to End of Treatment (EOT) in Mean Volume Voided Per Micturition — 14.0; 24.9; 34.5; 36.4 mL — p=0.97
Male Erectile Disorder · Prostate Cancer · Radiation Toxicity
Primary: International Index of Erectile Function (IIEF) — 14.62; 14.26; 11.82 units on a scale
Ductal Breast Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer
Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells
Hypothyroidism
Primary: Percentage of Participants That Do Not Need a Change of Dose — 32.9 percentage of participants
Ciliary Body and Choroid Melanoma, Medium/Large Size · Ciliary Body and Choroid Melanoma, Small Size · Iris Melanoma
Primary: Number of Participants With Response — 0; 0; 8; 9 participants
Colon Cancer · Colorectal Cancer · Gastrointestinal Cancer
Primary: Part 1: Number of Participants With Dose-limiting Toxicities (DLT) — 0 participants
Heart Failure · Kidney Dysfunction
Primary: Renal Function as Measured by Glomerular Filtration Rate (GFR) at Baseline and in Response to Decreasing Furosemide Dose — 77; 42; 73; 50 ml/min — p=<0.05
Colonic Neoplasms
Primary: Concentration of [6R]-5,10-methylene-THF in Tumor Tissue — 1871; 959; 4725; 2393 pmol/g — p=0.0323
Recurrent Uterine Corpus Sarcoma · Uterine Corpus Leiomyosarcoma
Primary: Progression-free Survival (PFS) > 6 Months — 0.0 percentage of participants
Hormone-Resistant Prostate Cancer · Metastatic Malignant Neoplasm in the Bone · Recurrent Prostate Carcinoma
Primary: Changes in 18F-fluoride PET (SUV) - Tumor Bone — -6.67 SUVmax — p=<0.001
Pulmonary Disease, Chronic Obstructive
Primary: Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) (0-3hours) Response After Single-dose Administration — 0.014; 0.233; 0.266 Litres — p=<0.0001
Pulmonary Disease, Chronic Obstructive
Primary: Trough FEV1 Response — 0.071; 0.125; 0.136; 0.155 Litres
Postoperative Pain · Postoperative Nausea and Vomiting
Primary: Maximum Severity of Post-operative Pain — 37; 26; 13; 21 participants — p=0.033
HIV-1 Infection
Primary: Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) — -1.51; -2.40 percentage change — p=<0.001
Pancreatic Cancer
Primary: Safety of Combining the Pancreatic Tumor Vaccine in Sequence With Cyclophosphamide and Erbitux. Safety is Defined as the Number of Treatment-related Grade 3 or 4 Adverse…